University of Oxford

Pharminox Ltd, a private oncology R&D company backed by IP Group, is to carry out joint research into novel small molecule chemotherapeutics with Schering-Plough.

A spin-out from Oxford University is looking to attract the attention of equity investors and pharmaceutical companies by focusing on the discovery and development of small molecules to treat cancer

IP2IPO Group, which specialises in commercialising university technology, has made an exclusive 25-year deal with the University of Bristol to form spin-out companies from the university. Analysts greeted the deal as a boost for the company.